Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18415270 | METHOD OF TREATING OR REDUCING EFP | January 2024 | November 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18518528 | COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOME | November 2023 | May 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18494126 | METHODS OF TREATMENT FOR FUNCTIONAL DECLINE IN HIPPOCAMPUS, FOR IMPROVING RECOGNITION MEMORY ACCURACY, AND FOR IMPROVING HIPPOCAMPAL NEURONAL FUNCTION | October 2023 | November 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18465214 | DIFFERENTIATION AND ENRICHMENT OF ISLET-LIKE CELLS FROM HUMAN PLURIPOTENT STEM CELLS | September 2023 | December 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18301782 | Multilayered Vascular Tubes | April 2023 | October 2025 | Abandon | 30 | 3 | 0 | No | No |
| 18185049 | HUMAN MILK PERMEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME | March 2023 | January 2025 | Abandon | 22 | 1 | 1 | No | No |
| 17918699 | Methods and Compositions For Reducing Joint Inflammation Using Mesenchymal Stem Cells | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17929364 | METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL LINE FROM MESENCHYMAL STEM CELLS, AND CELL LINE OBTAINED THEREBY | September 2022 | November 2025 | Abandon | 38 | 3 | 1 | No | No |
| 17822946 | IN VITRO DRUG METABOLISM REAGENT AND USES THEREOF | August 2022 | February 2026 | Abandon | 41 | 1 | 1 | No | No |
| 17627905 | COMPOSITION FOR REGENERATING NUCLEUS PULPOSUS | June 2022 | November 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17638026 | METHOD FOR PRODUCING VASCULAR ENDOTHELIAL STEM CELL | February 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17559953 | DRUG COCKTAIL ANALYSES USING MICROSCALE VORTEX-ASSISTED ELECTROPORATION | December 2021 | September 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17556337 | PHARMACEUTICAL PREPARATION COMPRISING SUPERNATANT OF BLOOD MONONUCLEAR CELL CULTURE AND METHOD OF USE | December 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17618322 | MEANS FOR USE IN PREPARATION OF HYDROGEL BASED ON HYDROXYPHENYL DERIVATIVE OF HYALURONAN, METHOD OF HYDROGEL PREPARATION AND USE THEREOF | December 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17539767 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | December 2021 | November 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17522297 | INJECTABLE, PORE-FORMING HYDROGELS FOR MATERIALS-BASED CELL THERAPIES | November 2021 | July 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17519186 | MONITORING AND MODIFYING THE MICROBIOME IN PATIENTS WITH RECTOVAGINAL FISTULA | November 2021 | July 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17514619 | THREE-LAYER STRUCTURE INCLUDING EXTRA-CELLULAR MATRIX, SHEET-SHAPED CELL CULTURE, AND BIODEGRADABLE GEL | October 2021 | January 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17606750 | PREPARATION OF HUMAN ALLOGENEIC LIVER-DERIVED PROGENITOR CELLS | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17496734 | COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE | October 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17441714 | REDOX ENZYMES IN ANIMAL FEED COMPOSITIONS | September 2021 | February 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17465382 | Methods and Systems For Saccharification of Biomass | September 2021 | May 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17430634 | Cell-Free Compositions for ATP Regeneration and Uses Thereof | August 2021 | January 2026 | Abandon | 53 | 3 | 1 | No | No |
| 17379321 | METHOD OF PURIFYING ACTIVE SOLUBLE MATRIX METALLOPROTEINASES | July 2021 | November 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17420732 | ENHANCING EPITHELIAL OR ENDOTHELIAL BARRIER FUNCTION | July 2021 | July 2025 | Abandon | 48 | 4 | 1 | No | No |
| 17344414 | ENZYME COMPOSITIONS AND USE THEREOF FOR WOUND HEALING | June 2021 | May 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17302747 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN ANIMALS | May 2021 | November 2025 | Abandon | 54 | 3 | 1 | No | Yes |
| 17291081 | METHOD FOR MANUFACTURING HIGHLY PURIFIED LACTOFERRIN AND LACTOPEROXIDASE FROM MILK, COLOSTRUM AND ACID OR SWEET WHEY | May 2021 | May 2025 | Abandon | 49 | 3 | 1 | No | No |
| 17287670 | USE OF GLUCOSYLCERAMIDE SYNTHASE GENE-DEFICIENT T CELL AND THERAPEUTIC UTILIZATION THEREOF | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17236736 | METHODS OF GANGLIOSIDE PRODUCTION | April 2021 | May 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17223123 | MEDICAL-GRADE HONEY FOR GROWTH ENHANCEMENT OF INFANTS | April 2021 | May 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17281535 | EXTRACELLULAR VESICLES FOR REPLACEMENT OF UREA CYCLE PROTEINS & NUCLEIC ACIDS | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17212528 | METHOD FOR CONTINUOUS SECOND-GENERATION ETHANOL PRODUCTION IN SIMULTANEOUS SACCHARIFICATION AND CO-FERMENTATION PROCESS | March 2021 | November 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17274601 | ANIMAL FEED COMPOSITION AND USE THEREOF | March 2021 | March 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17269235 | ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE, METHODS, USES, APPARATUSES AND SYSTEMS ASSOCIATED THEREWITH | February 2021 | August 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17269238 | ENZYMATIC COMPOSITIONS FOR CARBOHYDRATE ANTIGEN CLEAVAGE ON DONOR ORGANS, METHODS AND USES ASSOCIATED THEREWITH | February 2021 | July 2024 | Abandon | 41 | 2 | 1 | Yes | No |
| 17163065 | Method of Treating a Disorder of Cognitive Performance or Memory | January 2021 | May 2024 | Abandon | 39 | 2 | 0 | No | Yes |
| 17152543 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | January 2021 | October 2025 | Abandon | 57 | 7 | 1 | Yes | No |
| 17259898 | MODEL FOR IN-VITRO SIMULATION OF THE BEHAVIOUR OF DYSFUNCTIONAL VESSELS | January 2021 | November 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17142932 | In vitro Transcription-Translation Metabolic Networks to Measure Quantity or Activity of Enzymes | January 2021 | June 2025 | Abandon | 53 | 3 | 1 | No | No |
| 17254029 | USE OF AN EXTRACELLULAR MATRIX (ECM) HYDROGEL AS AN ESOPHAGEAL SUBMUCOSAL FLUID CUSHION | December 2020 | July 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17120042 | CANNABINOID ENRICHED COMPOSITION AND METHOD OF USING | December 2020 | October 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16953002 | INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOF | November 2020 | February 2026 | Abandon | 60 | 4 | 1 | Yes | No |
| 17089469 | COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOME | November 2020 | January 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17075486 | SSCF PROCESS FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASS AND 2G RESIDUAL BIOMASS | October 2020 | July 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17045110 | GENE THERAPY FOR OXIDATIVE STRESS | October 2020 | February 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17043885 | USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | September 2020 | April 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17012531 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | September 2020 | August 2025 | Abandon | 59 | 3 | 1 | No | Yes |
| 16989701 | HOLDERS FOR BIOREACTOR SENSORS, BIOREACTORS HAVING SUCH HOLDERS, AND METHODS CULTURING BIOLOGICAL MATERIAL | August 2020 | April 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16937451 | METHOD FOR PRODUCING ANTIGEN-SPECIFIC T CELLS | July 2020 | February 2025 | Abandon | 54 | 3 | 1 | No | No |
| 16935639 | TRITURATION DEVICES FOR TISSUE DISAGGREGATION | July 2020 | May 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16892156 | PLURIPOTENT STEM CELL-DERIVED MACROPHAGE CAPABLE OF TARGETING TUMOR CELLS AND PREPARATION METHOD THEREOF | June 2020 | October 2024 | Abandon | 52 | 2 | 1 | No | No |
| 15929579 | BACTERIAL STRAIN COMPOSITIONS AND METHODS OF USING SAME | May 2020 | July 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16757181 | Anaerobic Cell-Free Systems and Environments and Methods for Making and Using Same | April 2020 | July 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16648349 | RIBOFLAVINASE ENZYMES AND THEIR USE TO PREVENT OFF FLAVOR IN BREWING | March 2020 | October 2024 | Abandon | 55 | 2 | 1 | No | No |
| 16643713 | AN AGENT, A DEVICE AND A BLOOD-CIRCULATION SYSTEM FOR TREATING LYSOSOMAL STORAGE DISEASES, AND A METHOD FOR TREATING LYSOSOMAL STORAGE DISEASES | March 2020 | August 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16806404 | Dosing Regimens For The Treatment Of Fabry Disease | March 2020 | October 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16640807 | TRANSPOSON SYSTEM AND METHODS OF USE | February 2020 | November 2023 | Abandon | 44 | 2 | 0 | No | No |
| 16639624 | Methods for Antimicrobial Susceptibility Testing | February 2020 | October 2023 | Abandon | 44 | 3 | 0 | No | No |
| 16635142 | CARDIOSPHERE-DERIVED CELLS AND THEIR EXTRACELLULAR VESICLES FOR TREATMENT AND PREVENTION OF CANCER | January 2020 | May 2024 | Abandon | 51 | 3 | 1 | No | No |
| 16751708 | Stable Bioactive Substances and Methods of Making | January 2020 | April 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16710545 | BIOLOGICAL COMPOSITION FOR DEGRADING PLANT PESTICIDE RESIDUES AND THE APPLICATION THEREOF | December 2019 | January 2024 | Abandon | 49 | 4 | 0 | No | No |
| 16684142 | METHOD FOR TREATMENT OF INFERTILITY, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF INFERTILITY AND METHOD FOR PRODUCING THE SAME | November 2019 | March 2023 | Abandon | 40 | 4 | 0 | Yes | No |
| 16606795 | METHOD FOR PREPARING CANCER STEMNESS CELL LINE THROUGH METABOLIC STRESS, AND CANCER CELL PREPARED THROUGH SAME | October 2019 | December 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16603927 | METHODS FOR IDENTIFYING THE HEALTH STATE OF HYPOPHOSPHATASIA (HPP) PATIENTS | October 2019 | April 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16540934 | Multilayered Vascular Tubes | August 2019 | December 2023 | Abandon | 52 | 4 | 0 | No | No |
| 16532801 | Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample | August 2019 | December 2021 | Abandon | 28 | 1 | 0 | No | No |
| 16531605 | Platform for Engineered Implantable Tissues and Organs and Methods of Making the Same | August 2019 | July 2024 | Abandon | 59 | 4 | 1 | No | No |
| 16465934 | MAGNETICALLY IMMOBILIZED METABOLIC ENZYMES AND COFACTOR SYSTEMS | May 2019 | October 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16422052 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | No | No |
| 16422023 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | Yes | No |
| 16422031 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | No | No |
| 16422045 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | November 2020 | Abandon | 18 | 1 | 1 | No | No |
| 16422059 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | May 2019 | October 2020 | Abandon | 17 | 1 | 1 | No | No |
| 16419904 | Process and Apparatus for Producing Mycelium Biomaterial | May 2019 | April 2024 | Abandon | 59 | 5 | 0 | No | No |
| 16397159 | DETERMINATION OF A CONSTITUENT RELATED PROPERTY OF A MULTI-CONSTITUENT SAMPLE | April 2019 | June 2022 | Abandon | 38 | 2 | 0 | Yes | No |
| 16382443 | METHOD FOR MANUFACTURING A STABLE AQUEOUS SOLUTION OF BETA-AMYLASE, AQUEOUS SOLUTION OBTAINED AND USES THEREOF | April 2019 | August 2022 | Abandon | 40 | 4 | 1 | No | No |
| 16370109 | COMPOSITIONS FOR TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POST-MENOPAUSAL DYSPAREUNIA, AND/OR OOPHORECTOMIZED FEMALES AND TREATMENT METHODS THEREWITH | March 2019 | February 2024 | Abandon | 59 | 5 | 0 | Yes | No |
| 16332422 | Lin28a ACTIVATOR AND USE THEREFOR | March 2019 | November 2023 | Abandon | 57 | 4 | 0 | Yes | No |
| 16351045 | METHOD FOR SECOND GENERATION ETHANOL PRODUCTION FROM LIGNOCELLULOSIC BIOMASS | March 2019 | June 2024 | Abandon | 60 | 6 | 0 | Yes | No |
| 16277571 | Skin Care Compositions | February 2019 | July 2022 | Abandon | 41 | 3 | 0 | No | No |
| 16318684 | USE OF PROBIOTICS IN THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS | January 2019 | November 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16318037 | CHROMATIN PROTECTIVE THERAPEUTICS AND CHROMATIN HETEROGENEITY | January 2019 | December 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16237933 | COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE | January 2019 | February 2022 | Abandon | 37 | 4 | 0 | No | No |
| 16313359 | Cell enclosure device and use for same | December 2018 | July 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16216091 | AUTOMATED CELL COLLECTION AND SMEARING | December 2018 | February 2024 | Abandon | 60 | 4 | 0 | No | No |
| 16209544 | COMPOSITION COMPRISING AN ACTIVATED MICROBIAL BIOMASS | December 2018 | June 2022 | Abandon | 42 | 4 | 1 | Yes | No |
| 16173536 | COMPOSITION USEFUL FOR THE PREPARATION OF A SUPPOSITORY | October 2018 | February 2022 | Abandon | 39 | 3 | 1 | No | No |
| 16172606 | ECM COMPOSITION, TUMOR MICROENVIRONMENT PLATFORM AND METHODS THEREOF | October 2018 | October 2020 | Abandon | 24 | 1 | 0 | No | No |
| 16165712 | COMPOSITIONS CONTAINING EUGLENA GRACILIS FOR VIRAL PROTECTION AND RELATED METHODS | October 2018 | September 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 16094846 | Composition of proenzymes for cancer treatment | October 2018 | November 2024 | Abandon | 60 | 6 | 1 | No | No |
| 16094384 | METHODS OF DEBRIDEMENT OF CHRONIC WOUNDS | October 2018 | October 2024 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 16087028 | Device for Storing Blood and Method for Use Thereof | September 2018 | March 2023 | Abandon | 54 | 0 | 1 | No | No |
| 16129870 | PROTEIN KINASE C INHIBITION TO EXTEND TISSUE PLASMINOGEN ACTIVATOR TREATMENT FOR ISCHEMIC DISEASE | September 2018 | November 2024 | Abandon | 60 | 9 | 1 | Yes | No |
| 16081975 | METHODS FOR EXPERIMENTAL EVOLUTION OF NATURAL AND SYNTHETIC MICROBES | September 2018 | May 2023 | Abandon | 56 | 3 | 1 | No | No |
| 16074936 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | August 2018 | November 2020 | Abandon | 27 | 0 | 1 | No | No |
| 16071340 | BICOMPATIBLE PEPTIDEBIOCOMPATIBLE PEPTIDES FOR INHIBITION OF AGGREGATION OF B-AMYLOID PROTEIN | July 2018 | January 2025 | Abandon | 60 | 3 | 1 | No | No |
| 15973903 | Compositions and Methods for Spine Fusion Procedures | May 2018 | August 2021 | Abandon | 39 | 2 | 0 | No | No |
| 15766627 | High-Throughput Platform for Bioprinting Tissue Modules | April 2018 | November 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 15946524 | New A-PRP Medical Device & Tissue Engineering Composition, Manufacturing Machines And Process | April 2018 | December 2023 | Abandon | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSS, NATALIE M.
With a 35.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOSS, NATALIE M works in Art Unit 1653 and has examined 567 patent applications in our dataset. With an allowance rate of 32.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner MOSS, NATALIE M's allowance rate of 32.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOSS, NATALIE M receive 2.71 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MOSS, NATALIE M is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +27.6% benefit to allowance rate for applications examined by MOSS, NATALIE M. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 7.8% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 35.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 90.9% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.